# Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

> **NCT05757843** · PHASE2 · WITHDRAWN · sponsor: **Indiana University**

## Conditions studied

- NSCLC, Stage III

## Interventions

- **DIAGNOSTIC_TEST:** Signatera ctDNA test
- **DRUG:** Durvalumab

## Key facts

- **NCT ID:** NCT05757843
- **Lead sponsor:** Indiana University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-09-13
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to identify patients who meet eligibility requirements of tissue needed for analysis.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05757843

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05757843, "Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05757843. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*